Search
forLearn
5 / 801 resultslearn Trichogen
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Iodopropynyl Butylcarbamate
Research
5 / 198 results
research Down-RANKing the Threat of HSV-1: RANKL Upregulates MHC-Class-I-Restricted Anti-Viral Immunity in Herpes Simplex Virus Infection
RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.
research Bad Hair Day: Testosterone and Wnts
Testosterone can both promote hair growth and cause baldness by affecting hair growth signals.
research R hodococcus equi: Clinical Manifestations, Virulence, and Immunity
Rhodococcus equi causes severe pneumonia in young foals, and effective vaccines are needed due to foals' weak immune responses.
research Dissecting the microenvironment around biosynthetic scaffolds in murine skin wound healing
Different scaffold patterns improve wound healing and immune response in mouse skin, with aligned patterns being particularly effective.
research What’s Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses
Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.
Community Join
5 / 1000+ resultscommunity Binding affinity does not equal potency for anti androgens? Comparing pyrilutimide to cb-03-01
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.